Sleep Heart Health Study

Participant taking angiotensin-converting-enzyme inhibitor (ACE) INHIBITORS WITHOUT DIURETICS within two weeks of the Sleep Heart Health Study Visit One (SHHS1) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking angiotensin-converting-enzyme inhibitor (ACE) INHIBITORS WITH DIURETICS within two weeks of the Sleep Heart Health Study Visit One (SHHS1) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking ANTI-ARRHYTHMICS, CLASS 1A within two weeks of the Sleep Heart Health Study Visit One (SHHS1) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking ANTI-ARRHYTHMICS, CLASS 1B within two weeks of the Sleep Heart Health Study Visit One (SHHS1) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking ANTI-ARRHYTHMICS, CLASS 1C within two weeks of the Sleep Heart Health Study Visit One (SHHS1) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking ANTI-ARRHYTHMICS, CLASS 3 within two weeks of the Sleep Heart Health Study Visit One (SHHS1) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking BENZODIAZEPINES within two weeks of the Sleep Heart Health Study Visit One (SHHS1) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking BETA-BLOCKERS WITHOUT DIURETICS within two weeks of the Sleep Heart Health Study Visit One (SHHS1) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking BETA-BLOCKERS WITH DIURETICS within two weeks of the Sleep Heart Health Study Visit One (SHHS1) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking ANY CALCIUM-CHANNEL BLOCKER = CCIR OR CCBSR OR CCBT within two weeks of the Sleep Heart Health Study Visit One (SHHS1) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking ANY DIURETIC within two weeks of the Sleep Heart Health Study Visit One (SHHS1) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking ANY ANTI-HYPERTENSIVE MEDICATION within two weeks of the Sleep Heart Health Study Visit One (SHHS1) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking INSULINS within two weeks of the Sleep Heart Health Study Visit One (SHHS1) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking INHALED STEROIDS FOR ASTHMA within two weeks of the Sleep Heart Health Study Visit One (SHHS1) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking ANY LIPID-LOWERING MEDICATION within two weeks of the Sleep Heart Health Study Visit One (SHHS1) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking NON-STEROIDAL ANTI-INFLAMMATORY AGENTS, EXCLUDING ASPIRIN within two weeks of the Sleep Heart Health Study Visit One (SHHS1) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking NON-TRICYCLIC ANTIDEPRESSANTS OTHER THAN monoamine oxidase inhibitor (MAOI) within two weeks of the Sleep Heart Health Study Visit One (SHHS1) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking NITRATES within two weeks of the Sleep Heart Health Study Visit One (SHHS1) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking ORAL HYPOGLYCEMIC AGENTS within two weeks of the Sleep Heart Health Study Visit One (SHHS1) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking ORAL STEROIDS within two weeks of the Sleep Heart Health Study Visit One (SHHS1) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking TRICYLIC ANTI-DEPRESSANTS within two weeks of the Sleep Heart Health Study Visit One (SHHS1) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking angiotensin-converting-enzyme inhibitor (ACE) INHIBITORS WITHOUT DIURETICS within two weeks of the Sleep Heart Health Study Visit Two (SHHS2) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking angiotensin-converting-enzyme inhibitor (ACE) INHIBITORS WITH DIURETICS within two weeks of the Sleep Heart Health Study Visit Two (SHHS2) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking BENZODIAZEPINES within two weeks of the Sleep Heart Health Study Visit Two (SHHS2) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking BETA-BLOCKERS WITHOUT DIURETICS within two weeks of the Sleep Heart Health Study Visit Two (SHHS2) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking BETA-BLOCKERS WITH DIURETICS within two weeks of the Sleep Heart Health Study Visit Two (SHHS2) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking ANY DIURETIC within two weeks of the Sleep Heart Health Study Visit Two (SHHS2) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking ANY ANTI-HYPERTENSIVE MEDICATION within two weeks of the Sleep Heart Health Study Visit Two (SHHS2) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking INSULINS within two weeks of the Sleep Heart Health Study Visit Two (SHHS2) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking INHALED STEROIDS FOR ASTHMA within two weeks of the Sleep Heart Health Study Visit Two (SHHS2) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking ANY LIPID-LOWERING MEDICATION within two weeks of the Sleep Heart Health Study Visit Two (SHHS2) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking MISCELLANEOUS LIPID-LOWERING DRUGS within two weeks of the Sleep Heart Health Study Visit Two (SHHS2) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking ORAL ANTI-INFLAMMATORY ASTHMA DRUGS (LEUKOTRIENE RECEPTOR ANTAGONISTS AND INHIBITORS OF LIPO-OXYGENASE) within two weeks of the Sleep Heart Health Study Visit Two (SHHS2) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking ORAL HYPOGLYCEMIC AGENTS within two weeks of the Sleep Heart Health Study Visit Two (SHHS2) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking ORAL STEROIDS within two weeks of the Sleep Heart Health Study Visit Two (SHHS2) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking TRICYLIC ANTI-DEPRESSANTS within two weeks of the Sleep Heart Health Study Visit Two (SHHS2) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Usual Alcohol Intake per day

Lifetime cigarette smoking: pack years

Parent Cohort reported Diabetes Status

1. Has a doctor ever told you that you have the following? a. Emphysema

1. Has a doctor ever told you that you have the following? b. Chronic bronchitis

1. Has a doctor ever told you that you have the following? c. chronic obstructive pulmonary disease (COPD)

1. Has a doctor ever told you that you have the following? d. Asthma

e. Do you still have asthma?

16. Has a doctor ever told you that you have the following? restless leg syndrome (RLS)?

Hypertension (HTN) Status based on 2nd and 3rd blood pressure readings OR being treated with hypertension (HTN) meds

Derived hypertension (HTN) classification (based on blood pressure measurements, history of hypertension (HTN) dx, and medication use)

Participant taking ALPHA-BLOCKERS WITHOUT DIURETICS within two weeks of the Sleep Heart Health Study Visit One (SHHS1) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking ALPHA-BLOCKERS WITH DIURETICS within two weeks of the Sleep Heart Health Study Visit One (SHHS1) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking ASPIRIN FROM 280804 (ANTI-INFLAM AGENTS) within two weeks of the Sleep Heart Health Study Visit One (SHHS1) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking BILE-ACID SEQUESTRANTS within two weeks of the Sleep Heart Health Study Visit One (SHHS1) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking IMMEDIATE-RELEASE CCBS = NIFIR OR DIHIR OR VERIR OR DLTIR within two weeks of the Sleep Heart Health Study Visit One (SHHS1) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking SLOW-RELEASE CCBS = NIFSR OR DIHSR OR VERSR OR DLTSR OR AMLOD within two weeks of the Sleep Heart Health Study Visit One (SHHS1) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking DIGITALIS PREPARATIONS within two weeks of the Sleep Heart Health Study Visit One (SHHS1) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking ESTROGENS, EXCLUDING VAGINAL CREAMS within two weeks of the Sleep Heart Health Study Visit One (SHHS1) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking THIAZIDE DIURETICS WITHOUT K-SPARING AGENTS within two weeks of the Sleep Heart Health Study Visit One (SHHS1) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking THIAZIDE DIURETICS WITH K-SPARING AGENTS within two weeks of the Sleep Heart Health Study Visit One (SHHS1) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking LOOP DIURETICS within two weeks of the Sleep Heart Health Study Visit One (SHHS1) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking NIACIN AND NICOTINIC ACID within two weeks of the Sleep Heart Health Study Visit One (SHHS1) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Doctor of Medicine (MD) prescribed nitro in last year?

Participant taking PHOSPHODIESTERASE INHIBITORS within two weeks of the Sleep Heart Health Study Visit One (SHHS1) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking PREMARIN (CONJUGATED ESTROGENS) within two weeks of the Sleep Heart Health Study Visit One (SHHS1) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking PROGESTINS within two weeks of the Sleep Heart Health Study Visit One (SHHS1) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking PERIPHERAL VASODILATORS, EXCLUDE DIPYRIDAMOLE within two weeks of the Sleep Heart Health Study Visit One (SHHS1) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking SYMPATHOMIMETICS, ORAL AND INHALED within two weeks of the Sleep Heart Health Study Visit One (SHHS1) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking THYROID AGENTS within two weeks of the Sleep Heart Health Study Visit One (SHHS1) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking VASODILATORS, A MIXED GROUP within two weeks of the Sleep Heart Health Study Visit One (SHHS1) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking VASODILATORS WITH DIURETICS, A MIXED GROUP within two weeks of the Sleep Heart Health Study Visit One (SHHS1) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking ORAL ANTICOAGULANTS INCLUDING WARFARIN, COUMADIN, AND ANISINDIONE within two weeks of the Sleep Heart Health Study Visit One (SHHS1) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking ANGIOTENSIN TYPE 2 ANTAGONISTS within two weeks of the Sleep Heart Health Study Visit Two (SHHS2) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking COMBINATIONS OF ANGIOTENSIN II ANTAGONISTS PLUS DIURETICS within two weeks of the Sleep Heart Health Study Visit Two (SHHS2) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking INHIBITORS OF Adenosine Diphosphate (ADP)-INDUCED PLATELET AGGREGATION within two weeks of the Sleep Heart Health Study Visit Two (SHHS2) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking ALPHA-GLUCOSIDASE INHIBITORS within two weeks of the Sleep Heart Health Study Visit Two (SHHS2) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking ALPHA-BLOCKERS WITHOUT DIURETICS within two weeks of the Sleep Heart Health Study Visit Two (SHHS2) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking ALPHA-BLOCKERS WITH DIURETICS within two weeks of the Sleep Heart Health Study Visit Two (SHHS2) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking ACETYLCHOLINE ESTERASE INHIBITORS FOR ALZHEIMERS within two weeks of the Sleep Heart Health Study Visit Two (SHHS2) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking AMLODIPINE within two weeks of the Sleep Heart Health Study Visit Two (SHHS2) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking ANTI-ARRHYTHMICS, CLASS 1A within two weeks of the Sleep Heart Health Study Visit Two (SHHS2) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking ANTI-ARRHYTHMICS, CLASS 1B within two weeks of the Sleep Heart Health Study Visit Two (SHHS2) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking ANTI-ARRHYTHMICS, CLASS 1C within two weeks of the Sleep Heart Health Study Visit Two (SHHS2) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking ANTI-ARRHYTHMICS, CLASS 3 within two weeks of the Sleep Heart Health Study Visit Two (SHHS2) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking ASPIRIN FROM 280804 (ANTI-INFLAM AGENTS) within two weeks of the Sleep Heart Health Study Visit Two (SHHS2) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking BILE-ACID SEQUESTRANTS within two weeks of the Sleep Heart Health Study Visit Two (SHHS2) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking BIGUANIDES within two weeks of the Sleep Heart Health Study Visit Two (SHHS2) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking ANY CALCIUM-CHANNEL BLOCKER = CCIR OR CCBSR OR CCBT within two weeks of the Sleep Heart Health Study Visit Two (SHHS2) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking IMMEDIATE-RELEASE CCBS = NIFIR OR DIHIR OR VERIR OR DLTIR within two weeks of the Sleep Heart Health Study Visit Two (SHHS2) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking SLOW-RELEASE CCBS = NIFSR OR DIHSR OR VERSR OR DLTSR OR AMLOD within two weeks of the Sleep Heart Health Study Visit Two (SHHS2) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking T-TYPE CALCIUM-CHANNEL BLOCKER within two weeks of the Sleep Heart Health Study Visit Two (SHHS2) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking COX-2 INHIBITORS (nonsteroidal anti-inflammatory drug (NSAID) AGENTS); SEPARATE FROM nonsteroidal anti-inflammatory drug (NSAID) VARIABLE within two weeks of the Sleep Heart Health Study Visit Two (SHHS2) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking DIGITALIS PREPARATIONS within two weeks of the Sleep Heart Health Study Visit Two (SHHS2) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking IMMEDIATE-RELEASE DIHYDROPYRIDINES OTHER THAN NIFEDIPINE within two weeks of the Sleep Heart Health Study Visit Two (SHHS2) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking SLOW-RELEASE DIHYDROPYRIDINES OTHER THAN NIFEDIPINE OR AMLOPIDINE within two weeks of the Sleep Heart Health Study Visit Two (SHHS2) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking IMMEDIATE-RELEASE DILTIAZEM within two weeks of the Sleep Heart Health Study Visit Two (SHHS2) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking SLOW-RELEASE DILTIAZEM within two weeks of the Sleep Heart Health Study Visit Two (SHHS2) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking ERECTILE DYSFUNCTION DRUGS within two weeks of the Sleep Heart Health Study Visit Two (SHHS2) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking ESTROGENS, EXCLUDING VAGINAL CREAMS within two weeks of the Sleep Heart Health Study Visit Two (SHHS2) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.

Participant taking FIBRATES within two weeks of the Sleep Heart Health Study Visit Two (SHHS2) visit. All medications were recorded during the interview, and medication information was later categorized by physician review.